The new neutrophil subset has been identified as a promising therapeutic target for trauma patients

ʻO ka subset neutrophil hou i ʻike ʻia he pahuhopu lapaʻau maikaʻi

The strength of the protein expression of the markers is shown on the viSNE map as a specific point, with low in blue, high in red. Money: Bachmaier, et al. ACS Nano

Using a protein nanoparticle they developed, scientists at the University of Illinois Chicago identified two subtypes of neutrophils and found that one of the subtypes could be used as a drug. for inflammatory diseases.

Neutrophils are a type of white blood cell that helps fight disease, cleanse the body of dead cells, and heal muscle pain. However, for people with medical conditions caused by chronic inflammation, such as arthritis or Crohn’s disease, or severe pain, such as sepsis, the role of neutrophils may be eliminated. . Neutrophils have been described as researching and contributing to the damage to the body – the second sword of inflammation. Unfortunately, current medications for inflammatory diseases direct neutrophils to suppress their inflammatory response, including their anti-infection and healing properties.

The UIC group is the first to classify neutrophils into two segments.

“Understanding the differences between these neutrophil subsets opens the door for further research on drugs to treat inflammatory diseases without increasing the risk of inflammatory bowel disease. patients, ”said research author Kurt Bachmaier, assistant professor in the department of medicine and modern medicine at the College of Medicine. , who led the research.

Bachmaier and his colleagues previously used a nanoparticle platform, made from a protein called albumin, to analyze how neutrophils work from bone marrow, blood, and flesh and light with nanoparticle. They found that some neutrophils brought albumin nanoparticles into the cell through a process called endocytosis, and others did not.

Scientists have named the subtype that quickly degrades the nanoparticle as ANP-high, because of the high albumin nanoparticle. Neutrophils that do not contain albumin nanoparticles are called ANP-low.

Further research with albumin nanoparticles has shown that the subtypes are different from cell membranes and they differ in their ability to help kill bacterial infections and their ability to injure. in cultivation. High levels of ANP neutrophils did not help kill bacteria but released a large number of reactive oxygen species as well as inflammatory chemokines and cytokines, contributing to inflammatory disease.

Because high ANP neutrophils are the ones that capture the nanoparticle, the scientists conducted intelligent experiments using the albumin nanoparticle to produce the drugs. They filled the nanoparticle with an anti-inflammatory drug and gave it to mice with sepsis. They found that mice treated with the drug-filled nanoparticle reduced symptoms of inflammation, but maintained neutrophilic host-defense.

“The albumin nanoparticle, which is filled with the drug, directly binds to the neutrophils high in ANP and releases their charge into the chamber, releasing its pathways,” Bachmaier said. “We found high ANP neutrophils not only in mice but in humans, opening up the possibility of neutrophil subset-specific targeted therapy for human inflammatory diseases.”

“Science could be the same – by looking for high ANP neutrophils, we have stopped rooting out of control in the treatment of bacterial cancer of these Janus -like cells,” he said. and senior writer Asrar Malik, Schweppe family. Honorary professor and head of the department of medicine and regenerative medicine.

These findings are presented in the article “Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury,” published in ACS Nanoa scientific journal of the American Chemical Society and the first nanotechnology journal.

The co-authors of the article are Andrew Stuart, Amitabha Mukhopadhyay, Sreeparna Chakraborty, Zhigang Hong, Li Wang, Yoshikazu Tsukasaki, Mark Maienschein-Cline, Balaji Ganesh, Prasad Kanteti and Jalees Rehman.

Sugar -bound nanoparticles target macrophages, inducing pulmonary fibrosis

More information:
Kurt Bachmaier et al, Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury, ACS Nano (2022). DOI: 10.1021 / acsnano.1c09762

Presented by the University of Illinois at Chicago

Directions: A new neutrophil subset identified as a promising treatment goal for neutrophils (2022, April 5) Retrieved 6 April 2022 from subset-therapeutic-inflammatory.html

This document is copyrighted. Except for appropriate action for the purpose of personal inquiry or research, no piece may be reproduced without permission. Information is provided for informational purposes only.

Related Posts

Leave a Reply

Your email address will not be published.